UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection

Gastroenterology (New York, N.Y. 1943), 2019-09, Vol.157 (3), p.624-636

2019

Volltextzugriff (PDF)

Anti-interleukin-23 agents for the treatment of ulcerative colitis

Expert opinion on biological therapy, 2020-04, Vol.20 (4), p.399-406

2020

Volltextzugriff (PDF)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

Gut, 2018-10, Vol.67 (10), p.1824-1835

2018

Volltextzugriff (PDF)

Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation

The ISME Journal, 2017-08, Vol.11 (8), p.1877-1889

2017

Volltextzugriff (PDF)

Top-down therapy for IBD: rationale and requisite evidence

Nature reviews. Gastroenterology & hepatology, 2010-02, Vol.7 (2), p.86-92

D'Haens, Geert R

2010

Volltextzugriff (PDF)

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial

Gut, 2019-07, Vol.68 (7), p.1162-1168

2019

Volltextzugriff (PDF)

Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis

Clinical gastroenterology and hepatology, 2021-11, Vol.19 (11), p.2333-2342

2021

Volltextzugriff (PDF)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study

Inflammatory bowel diseases, 2022-03, Vol.28 (4), p.495-501

2022

Volltextzugriff (PDF)

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis

Inflammatory bowel diseases, 2023-01, Vol.29 (1), p.62-69

2023

Volltextzugriff (PDF)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Gut, 2020-04, Vol.69 (4), p.658-664

2020

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study

Inflammatory bowel diseases, 2022-05, Vol.28 (5), p.689-699

2022

Volltextzugriff (PDF)

High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study

Inflammatory bowel diseases, 2021-03, Vol.27 (3), p.352-363

2021

Volltextzugriff (PDF)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies

Clinical pharmacology and therapeutics, 2022-07, Vol.112 (1), p.90-100

2022

Volltextzugriff (PDF)

Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD

Expert opinion on biological therapy, 2019-04, Vol.19 (4), p.361-366

2019

Volltextzugriff (PDF)

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

Journal of Crohn's and colitis, 2023-04, Vol.17 (3), p.338-351

2023

Volltextzugriff (PDF)

Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies

Scandinavian journal of gastroenterology, 2024, Vol.59 (2), p.169-175

2024

Volltextzugriff (PDF)

Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Promising, but Work in Progress

Inflammatory bowel diseases, 2022-05, Vol.28 (5), p.783-787

2022

Volltextzugriff (PDF)

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

Inflammatory bowel diseases, 2022-07, Vol.28 (7), p.1034-1044

2022

Volltextzugriff (PDF)

Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis

Inflammatory bowel diseases, 2023-11

2023

Volltextzugriff (PDF)

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

Gastroenterology (New York, N.Y. 1943), 2008-11, Vol.135 (5), p.1493-1499

2008

Volltextzugriff (PDF)

Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease

Clinical infectious diseases, 2020-02, Vol.70 (4), p.595-604

2020

Volltextzugriff (PDF)

Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice

Inflammatory bowel diseases, 2018-01, Vol.24 (1), p.67-77

2018

Volltextzugriff (PDF)

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2017-05, Vol.376 (18), p.1723-1736

2017

Volltextzugriff (PDF)

Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity

Inflammatory bowel diseases, 2019-04, Vol.25 (5), p.937-944

2019

Volltextzugriff (PDF)

Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial

Journal of Crohn's and colitis, 2024-06, Vol.18 (6), p.864-874

2024

Volltextzugriff (PDF)

1 – 25 von 583

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(577)
Mit Volltextzugriff
(493)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(17)
... seit 90 Tagen
(18)

Menü

Weitere Dienste

Einstellungen

Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection

Anti-interleukin-23 agents for the treatment of ulcerative colitis

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation

Top-down therapy for IBD: rationale and requisite evidence

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial

Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study

High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies

Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies

Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Promising, but Work in Progress

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease

Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity

Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial

Suchergebnisse filtern